The effect of protein binding in serum of eight cephem antibiotics (ceftazidime, ceftizoxime, cefotiam, cefmetazole, cefpiramide, cefazolin, cefuzonam, ceftriaxone) on their therapeutic efficacies was examined in mice with experimentally induced intraperitoneal infections or pneumonia. The relationship among therapeutic activity, in vitro antibacterial activity, total or free (unbound) levels in serum, and homogenized whole lung levels was investigated. In the intraperitoneal infection caused by Staphylococcus aureus or Klebsiella pneumoniae, the 50% effective doses (ED50s) of the cephem antibiotics correlated with the area under the concentration-time curve (AUC) values of free levels in serum and the MICs but not with those of total levels in serum. A linear relationship was seen between V/ED.0 values and AUC of free levels in serum/MIC valaues.
On the other hand, in mice with pneumonia caused by K. pneumoniae, the number of bacteria in the lung closely correlated with the AUC of the antibiotic concentration in lung tissue. There was a direct correlation between the levels in lung tissue and total levels in serum but not free levels in serum. The cephem antibiotics tested in this study were bound only slightly to homogenates of mouse lung. These results indicate that the effect of protein binding in serum on therapeutic efficacy against intraperitoneal infection differs from that against pulmonary infection.
The significance of antibiotic protein binding has been discussed for the past 40 years. Protein binding has two direct effects on therapeutic efficacy because it affects antibacterial activity and distribution. It is accepted that only the free fraction can act against bacteria (23, 29) . The effect of protein binding in serum on extravascular penetration is less clearly established. Although the effects of protein binding in serum on penetration into extravascular fluid and tissues has been studied in various animal (5, 7, 12, 31) and human (2, 3, 9, 27, 28, 33) models, the results were contradictory. Some of these studies show that the penetrability is primarily dependent on the free fraction in serum (2, 3, 9, 12, 27, 28, 33) , whereas others show the contrary (5, 7, 31) . The effect of protein binding on therapeutic efficacy was also examined in various animal models (1, 16, 17, 19, 20, 25) , but the results were inconclusive. The clinical significance of the effect of protein binding on therapeutic efficacy is still controversial.
In the study reported here, we investigated the effect of protein binding in serum on the therapeutic efficacy of eight cephem antibiotics which markedly differ in their extent of binding and in their in vitro activities against the test strains. The therapeutic efficacy of each compound was evaluated against intraperitoneal infections with Staphylococcus aureus or Klebsiella pneumoniae and pneumonia with K. pneumoniae, because the discrepancies of the results of studies on therapeutic efficacy may be due to differences in animal models. The relationship among the therapeutic activity, total or free antibiotic concentrations in serum, total lung homogenate levels, and in vitro susceptibility was investigated to clarify the factors that affect therapeutic efficacy.
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MATERIALS AND METHODS
Antimicrobial agents. The following antimicrobial agents were used: cefazolin (Fujisawa Pharmaceutical Co., Ltd.), cefotiam (Takeda Chemical Industries, Ltd.), cefmetazole (Sankyo Co., Ltd.), ceftizoxime (Fujisawa Pharmaceutical Co., Ltd.), ceftriaxone (Hoffman-LaRoche Inc.), cefpiramide (Sumitomo Pharmaceutical Co., Ltd.), ceftazidime (Glaxo Japan, Ltd.), and cefuzonam (Lederle Japan, Ltd.).
Bacteria. A standard strain of S. aureus Smith, a clinical isolate of K. pneumoniae 1, and K. pneumoniae B-54 were used. These strains were stored at 4°C on heart infusion agar slants (Difco Laboratories, Detroit, Mich.).
Antimicrobial susceptibility tests. MIC tests were carried out by serial twofold dilution in Mueller-Hinton agar (Difco) in petri dishes. The test organisms were incubated overnight in Mueller-Hinton broth (Difco). Overnight cultures were diluted 100-fold with Mueller-Hinton broth, and 0.01 ml of an inoculum containing 104 CFU was applied to agar plates with a multipoint replicating apparatus. These plates were incubated at 37°C for 18 h. The MIC was the lowest antibiotic concentration that inhibited macroscopic colonial growth during this incubation.
Protective The levels of the test antibiotics in lungs were determined in mice uninfected and infected with K. pneumoniae B-54 24 h after challenge. The mice were killed at specified intervals after drug dosing. The lungs were removed and blotted with filter paper. The lungs of the mice in each group were pooled and homogenized with a Polytron homogenizer after the addition of 2 ml of phosphate buffer per g of lung. The homogenates were centrifuged at 10,000 x g for 10 min. The drug concentration in each supernatant was bioassayed by using a standard curve prepared with the supernatant of lung homogenates of mice uninfected or infected with K. pneumoniae B-54. The hemoglobin levels in supernatants and blood specimens were determined by the cyanmethemoglobin method (15) Binding to lung homogenate. Lungs were removed from freshly killed mice, and blood was rinsed away by washing it in phosphate buffer. Lungs were blotted with filter paper and homogenized as 33% (wet weight) in phosphate buffer with a Polytron homogenizer. The binding to whole lung tissue homogenate at an antibiotic concentration of 30 jig/ml was determined by the ultrafiltration method with Visking tubing. After centrifugation at 1,000 x g for 30 min, the concentrations in the ultrafiltrate were determined by the microbiological assay. The hemoglobin level in the lung homogenate was determined by the method described above to estimate the percentage of contaminating blood. Control samples containing 30 [.g of the test antibiotics per ml in phosphate buffer containing the same volume of blood as the lung homogenate were handled in the same way. The binding (percent bound Therefore, the survival rates of drug B at certain doses of d, and d2 are equal to those of drug A at doses of (kllk2) d, and (kllk2) d2, respectively, as illustrated in Fig. 1 (Fig. 2) , the correlation was poor when the 1/ED50s were plotted against the AUC of total drug/MICs, especially in the case of ceftriaxone and cefuzonam, which had high levels of protein binding. On the other hand, a close correlation cold be seen when the 1/ED50s were plotted against the AUC of free drug/MICs (r = 0.97); this close correlation included ceftriaxone and cefuzonam. Similarly, the correlation between the 1/ED50s and the AUC of free drug/MICs was closer (r = 1.00) than that between the 1/ED50s and the AUC of total drug/MICs in the systemic infection with K. pneumoniae (Fig. 3) Table 2 , the penetrations of ceftriaxone and cefuzonam into the lung were good, despite their high degree of protein binding in serum. To clarify whether protein binding in serum affects the penetrations of the cephem antibiotics tested into the lung, the relationship between levels in serum and lung was investigated in mice uninfected and infected with K. pneumoniae B-54. The results are shown in Fig. 4 (uninfected mice) and Fig. 5 (infected mice) , in which the AUCs of levels in lung are plotted against those of levels in serum. A close correlation was seen between total levels in serum and those in lung, but not between free levels in serum and those in lung. The results indicate that the serum protein binding in serum does not directly affect the penetration into the lung under the experimental conditions used in this study. The levels in lungs in mice infected intranasally with K. pneumoniae B-54 24 h after challenge were compared with those in normal mice. As shown in Fig.  6 , the lung level AUCs of cephem antibiotics with high levels of protein binding in infected mice were higher than those in normal mice. On the other hand, there was not a significant difference between lung level AUCs in infected mice and those in normal mice for cephem antibiotics with low levels of protein binding. The results suggest that protein binding in serum also did not unfavorably affect the penetration of drug into the lung in infected mice in this study.
Relationship between the binding to protein in serum and lung homogenate. The binding of drug to whole lung tissue homogenate of mice was determined at a concentration of 30 ,ug/ml and was compared with that to protein in serum. The cephem antibiotics tested were 2.7 to 10.9% bound to lung is active against bacteria (23, 29) . However, results of studies on the effects of protein binding on penetration into extravascular fluid and tissues are contradictory. These discrepancies may be explained by differences in (i) experimental model and severity of inflammation and (ii) method of drug administration. For example, Peterson et al. (21, 22) 120. demonstrated that extravascular penetration is affected by the degree of protein binding in the extravascular fluid. The effect of administration method on the penetrability has been shown in studies in which animal (8, 30) and human (14) models were used. Therefore, the effect of protein binding in serum on therapeutic efficacy may depend on the infection model and the method of treatment. For these reasons, we studied the therapeutic efficacy of eight cephem antibiotics with different degrees of protein binding using two infection models and investigated the factors that affected the therapeutic results.
In the systemic infections induced by S. aureus or K. pneumoniae, therapeutically effective antibiotic doses correlated more closely with the levels of the free antibiotic in serum than with those of total antibiotic. The results indicate that the protective effect against systemic infection is determined mostly by the MIC and free drug levels. Thus, our results demonstrate an inhibitory effect of protein binding in serum on the in vivo efficacy of a drug against systemic infections.
On the other hand, the effect of protein binding in serum on therapeutic efficacy against localized infection differed from that against systemic infection. Mattie et al. (16) investigated this subject in renal infection, but that model did not seem to be appropriate for this purpose. Drug concentrations in the kidney are not determined only by the penetration from the blood because it is a drug-excreting organ. For this reason, we chose pneumonia as a localized infection model. In the experimental pneumonia induced by intranasal inoculation of K. pneumoniae, the direct inhibitory effect of protein binding in serum on therapeutic efficacy was not seen. The cephem antibiotics with high levels of protein binding in serum, such as ceftriaxone and cefuzonam, penetrated into the lung in proportion to their total levels in serum, but not to their free levels in serum. The antibiotics with high levels of protein binding showed higher levels in the lungs of mice with pneumonia than in those of normal mice. This can be explained by protein leakage from blood vessels because of inflammation caused by the infection. The cephem antibiotics tested in this study were (17) , who showed the direct correlation between the in vivo activity against intraperitoneal infection with S. aureus and protein' binding in serum in mice, using isoxazolyl penicillins with similar in vitro activities and pharmacokinetic properties. This phenomenon was also demonstrated by Muckter et al. (19) . Although we used the AUC as the pharmacokinetic parameter in Fig. 2 and 3 (31) showed that total concentrations of cefazolin and cephaloridine in interstitial fluid correlated with the total levels in serum but not with' the free levels in serum in dogs after a single intravenous administration. Levels of ceftriaxone and cefuzonam in the lungs of rats after a single dose (6, 10) were not lower than those of ceftizoxime (18) . On the other hand, Shimizu et al. (26) showed that tissue cage fluid levels of 3-lactam antibiotics given in a continuous infusion correlated with the free levels in the serum of rabbits. This different effect of protein binding on extravascular penetration can be explained as follows, according to the hypothesis of Rolinson (24) . The effect of protein binding on antibiotic levels in the tissues depends on the half-life in serum. When drugs are given in a drip infusion, levels in serum are maintained for a long period of time and the levels in tissue will eventually equilibrate with the free levels in serum. On the other hand, equilibrium will not be reached after a subcutaneous injection because of a limited period of time for diffusion to take place.' Thus, protein binding did not directly affect the therapeutic efficacy on experimental pneumonia in this study.
The following factors are regarded as artifacts that may modify our conclusions. (i) There may have been differences in the dosage regimen, i.e., a single dose 1 h after challenge for the intraperitoneal infection model and three doses at 4, 24 , and 36 h after challenge for the pneumonia model. Therapeutic efficacy against the pneumonia model after a single dose was investigated. Drugs were given subcutaneously 4 h after bacterial inoculation, and the numbers of viable bacteria in the lungs were determined 8 h after challenge. The differences in the therapeutic effects of each of the drugs after three doses was more remarkable than that after a single dose, but the relationship between the therapeutic effects did not significantly change (data not shown).
(ii) There may have been drug accumulation after the three repeated doses (at 4, 24, and 36 h after challenge) in the pneumonia model. The elimination half-life for ceftriaxone from serum was 1.4 h in mice after a single' subcutaneous administration. The half-lives of the other antibiotics were 0.2 to 0.38 h. Therefore, it seems that the drugs did not accumulate in the lungs under the experimental conditions of this study. (iii) There may have been an effect of the inoculum size on the MIC. The relationship between therapeutic efficacy and the AUC/MIC was investigated by using MICs at an inoculum size of 106 CFU. The MICs increased approximately twofold, but' the relationship between the MICs of cach of the drugs was not significantly different from that at an inoculum size of 104 CFU (data not shown). Therefore, the effect of inoculum size on MIC did not modify our conclusions.
Our findings indicate that the effect of protein binding in serum on therapeutic efficacy is influenced by the infection model usedi. There is no clinical evidence that a highly bound druig is inferior to a less bound drug, as pointed out by Wise (32) . Therefore, the experimental infection model and the mode of drug administration should be carefully designed to estimate the clinical efficacies of highly protein-bound drugs.
